NVS Novartis owns or makes a slew of pharmacopial needs for a variety of medical needs. Little dip during recent pullback. Watching Friday ads, all brand names no companies. All Novartis or made for another company by Novartis.
CBDS CVSI GWPH INSY OTC:EMHTF CBD oil as extracted from PCR HEMP has many pharmacological/nutraceutical benefits. * Sleeping better * Relieves stress / reducing anxiety * Pain Relief & joint pain - and is non-psychotropic (PCR HEMP contains < 0.3% THC and often less in CBD Oils) * Epilepsy and epileptic seizures * IBS/Crohn's disease studies in...
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
BLRX had a strong rally today and it's just getting started. In the related idea my price target was $1.34. Today's high was $1.78 Check out the weekly chart: Photo Finish. $1.34 was 1.618 extension level from Waves 1 & 2. Since the price-action broke $1.34 we will have an extended 3rd wave. I expect a very strong rally tomorrow, I will update in the...
The price has closed above the downtrend line started this year with consistent volumes. I opened a buy as I am expecting increasing volume and strenght in the next sessions. Tps are already highlighted on the right.
A possible corrective structure may be completed on NASDAQ:ACAD . This could have big upside potential. If we get a consolidation here I'd love to start trading it on the radar.
Strong buy after MA 200 has come with insane violence. After a pull back of few days we have seen the start of a new uptrend. First TP is around 26,7 dollars where the gap down has left its trail.
Will Women get an F&DA approval for their VIAGRA?? Good entry with LT target 4-5 if approved. This chart is for own use. Viewers come to own conclusions and appreciate comments and learning thoughts.
As showed in the chart $BHC comes from a long bullish flag. Price is reaching the buy zone where the major bullish trendline goes through. It's not yet a buy but we are approching such zone. Strategy: watch and wait.
BLRX BL-8040 Overview BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. Solid Tumors: In January 2016, BioLineRx entered into a collaboration with MSD, known as ...
$Teva is still positive in the uptrend although the candle of yesterday has turned some indicators in bearish position. Over the mid term bullish trend is still strong. Having said that next candles have to be monitored because on a monthly basis there is a potential dragon fly bearish, thus a prompt recover toward the upper edge of the bullish flag is important...
I am waiting for an entry long in $BHC but positive signs are already there especially RSI is giving an insight, MA 200 is almost close and it might be probable a new test. Monthly RSI is down and on a weekly basis price is approcing the pullback of the third bullish wave. For the time being, given the positive earnings release a bullish trend continuation is...
ENDP Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced...
$MYL: Bullish wedge is about to be completed as yesterday we have seen rising bullish pressure, actually price wasn't able to break out the upper edge and we have seen a sharp intraday pullback (about 3%). Today buyers are coming in, thus price is heading upper edge. Volumes are rising, MACD on a weekly basis turn positive. Test of mid and long term support as...
Pharmaceutical stocks represents a defensive asset when a positive market cycle is about to finish or when it is foreseen a cycle less positive than the previous one. In such context pharma stocks should have an advantage because of inelastic demand for such goods. Novartis ($NVS,$NOVN) is one of the candidate to break up as the price is moving in a triangle...
$MYL after the earnings release has lost ground: investors actually pushed back the price yesterday with a massive bearish candle over -6%. Although the picture for generics look less positive than expected in the years to come, we should consider that demand for such goods is always "on" and today's prices (for these companies) are keeping such trend embodied....
Vertex has consolidating the price in a bullish wedge. A key resistence zone is at 178.57, a break out of such edge is interesting because it might pull up the price toward new high records. Stock is under the radar
Celgene helped by the company's buyback has turned positive after a complicated year. Despite this in terms of foundamentals two drugs are on the way to be developped but such developments will be revealed in the next year so patient is a must for those who wants to invest of something concreate. On a technical point of view yesterday price faild to cross MA 200....